Effect of topical mometasone furoate on adenoidal lymphoid tissue: a light microscopic study

2019 ◽  
Vol 133 (2) ◽  
pp. 106-109 ◽  
Author(s):  
M R Ahmed ◽  
A S Abou-Halawa ◽  
I H Ibrahim ◽  
R F Zittoon ◽  
E F Y Makary
Keyword(s):  
Nasal Spray ◽  
Lymphoid Tissue ◽  
Topical Steroid ◽  
Upper Airway ◽  
Mometasone Furoate ◽  
Control Group ◽  
Adenoid Hypertrophy ◽  
Nasal Steroids ◽  
Grade 3 ◽  
Adenoidal Tissue

AbstractBackgroundAdenoid hypertrophy is a common cause of upper airway obstruction, and adenoidectomy is one of the most frequently performed operations in children. Topical nasal steroids can act directly on nasopharyngeal lymphoid tissue to decrease its reactive inflammatory changes and potentially reduce its size.ObjectiveTo study the light microscopic changes in adenoidal lymphoid tissue after one month of topical steroid use.MethodsTwenty-six children with adenoid hypertrophy grade 3 scheduled for adenoidectomy were randomly divided into two equal groups: one group received mometasone furoate aqueous nasal spray (Nasonex) 100 mcg/day for four weeks, and a control group received nasal normal saline 0.9 per cent for four weeks. The removed adenoids were examined histopathologically.ResultsAdenoidal tissue from the mometasone group had less reactive germinal centres and less spongiosis compared to the control group. The latter showed proliferating, reactive, variable sized and shaped lymphoid follicles, with congested blood vessels in the interfollicular areas.ConclusionThe use of intranasal mometasone furoate aqueous nasal spray (Nasonex) for one month reduced adenoidal tissue reactive cellular changes and its vascularity. This is, however, a pilot study; a longer treatment period is needed to assess the effect of treatment on adenoidal size.

scholarly journals Role of mometasone furoate nasal spray in children with adenoid hypertrophy: impact on life style changes

2020 ◽  
Vol 6 (9) ◽  
pp. 1709
Author(s):  
Venkatesha B. K. ◽  
Ravi Shekhar
Keyword(s):  
Nasal Obstruction ◽  
Nasal Spray ◽  
Statistical Tests ◽  
Nasal Congestion ◽  
Sleep Apnea Syndrome ◽  
Mometasone Furoate ◽  
Nasal Discharge ◽  
Adenoid Hypertrophy ◽  
Obstructive Sleep ◽  
Life Style Changes

<p class="abstract"><strong>Background:</strong> Adenoid hypertrophy (AH) is a common cause of upper airway obstruction and obstructive sleep apnea syndrome (OSAS) in children having major impact on child’s growth and development. Symptoms like nasal congestion, mouth breathing, nasal discharge, snoring, day time sleepiness, hyponasal voice, ear popping, and craniofacial abnormalities are observed. Adenoidectomy is considered the treatment of choice for symptomatic children. Co-existing medical illnesses and choice of surgical treatment is governed by the paediatricians and apprehensive parents. Need for conservative treatments in alleviating symptoms have been tried. Topical, intranasal administered, steroid preparations have been proven effective in the literature.</p><p class="abstract"><strong>Methods:</strong> In this prospective study, 35 symptomatic children (3-12 years) with adenoid hypertrophy were included. Each of the symptoms was scored from 0 (absent) to 4 (severe) over Visual Analogue Scale (VAS). Nasal obstruction index was calculated. Results of mometasone furoate nasal spray 100 microgram/day used once daily at the interval of 8 weeks and 12 weeks were analysed using statistical tests.  </p><p class="abstract"><strong>Results:</strong> A statistically significant reduction in nasal obstruction index and other symptoms were noted at the end of third month follow up.</p><p class="abstract"><strong>Conclusions:</strong> Mometasone furoate nasal spray caused improvements in outcomes of nasal obstruction, snoring, total nasal symptoms, ear symptoms and overall quality of life.</p>

scholarly journals Radioactive Merano SPA Treatment for Allergic Rhinitis Therapy

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Desiderio Passali ◽  
Giacomo Gabelli ◽  
Giulio Cesare Passali ◽  
Roberto Magnato ◽  
Stefan Platzgummer ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Spray ◽  
Clinical Efficacy ◽  
Thermal Water ◽  
Hot Springs ◽  
Hot Spring ◽  
Pharmacological Therapy ◽  
Mometasone Furoate ◽  
Adjunctive Treatment ◽  
Control Group

Allergic rhinitis is a common nasal disorder with a high impact on quality of life, high social costs in therapies, and a natural development towards asthma. Pharmacological therapy is based on several genres of medications, of which intranasal corticosteroids are currently the most widespread. Thermal water treatment has traditionally been used as adjunctive treatment for chronic rhinitis and sinusitis. The present study was carried out to assess the clinical efficacy of nasal inhalation of radioactive oligomineral water vapours from the Merano hot spring and to compare it with the clinical efficacy of mometasone furoate nasal spray. A comparative prospective study was performed in 90 allergic patients treated at Merano hot springs: a group of 54 subjects treated with radioactive thermal oligomineral water and a control group of 36 subjects treated with mometasone nasal spray. Patients of both groups were assessed before and after treatment by Sino-Nasal Outcome Test questionnaire, active anterior rhinomanometry with flow and resistance monitoring, measurement of mucociliary transport time, and cytological examination of nasal brushing/scraping. The study showed that inhalation treatment with radioactive hydrofluoric thermal water for two weeks produces an objective clinical and cytological improvement in allergic patients, similar to that obtained with mometasone furoate nasal spray.

Role of mometasone furoate aqueous nasal spray for management of adenoidal hypertrophy in children

2014 ◽  
Vol 128 (12) ◽  
pp. 1060-1066 ◽  
Author(s):  
R Bhargava ◽  
A Chakravarti
Keyword(s):  
Quality Of Life ◽  
Nasal Spray ◽  
Mometasone Furoate ◽  
Controlled Study ◽  
Control Group ◽  
Score Change ◽  
Double Blind ◽  
Adenoidal Hypertrophy

AbstractObjectives:To study the role of mometasone furoate aqueous nasal spray for the management of adenoidal hypertrophy in children with more than 50 per cent obstruction, and to assess its impact on change in quality of life.Methods:A prospective, randomised, double-blind, interventional placebo-controlled study was conducted. A total of 100 children aged 2–12 years completed treatment and follow up. The symptoms and degree of obstruction were evaluated by nasopharyngoscopy conducted pre-treatment and 24 weeks post-treatment. Subjects received mometasone furoate nasal spray at a daily dose of 200 µg for 8 weeks, followed by a dose of 200 µg on alternate days for 16 weeks. Results were compared with those of a matched control group who were given saline nasal spray.Results:With mometasone treatment, there was an 89.8 per cent reduction in clinical symptom score, and the degree of obstruction dropped from 87 to 72 per cent (p < 0.0001). A statistically significant change in quality of life scores was seen in patients treated with the mometasone nasal spray (score change of 37.47) as compared with those given saline nasal spray (score change of 11.25) (p = 0.0001).Conclusion:Mometasone nasal spray appears to be effective in treating children with obstructive adenoids.

S102 – Mometasone Furoate Reduces Severity of Adenoidal Hypertrophy

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P111-P112
Author(s):  
Talal Nsouli
Keyword(s):  
Treatment Group ◽  
Skin Prick Test ◽  
Upper Airway ◽  
Mometasone Furoate ◽  
Control Group ◽  
Positive Skin Prick Test ◽  
Positive Skin ◽  
Prick Test ◽  
History Of ◽  
Adenoidal Hypertrophy

Objectives Allergic rhinitis (AR) is a risk factor for adenoidal hypertrophy—the adenoids are the lymphoid tissue closest to the nasal mucosa—and results in upper airway obstruction and snoring. The efficacy of mometasone furoate nasal spray (MFNS) in reducing gland size and degree of snoring in subjects with adenoidal hypertrophy and concomitant AR was assessed. Methods Children 5 to 10 years old with adenoidal hypertrophy and a history of chronic nasal obstruction and snoring received MFNS 50 mcg QD in each nostril. 16 subjects with AR diagnosed by positive skin prick test to environmental allergens comprised the treatment group, and 8 subjects with no history of AR and a negative skin prick test comprised the control group. Efficacy variables, assessed at Weeks 0 (baseline), 4, and 8, were change in size of the adenoid gland, evaluated by flexible fiber-optic and graded as a percentage according to degree of obliteration of the choanae, and change in degree of snoring, evaluated on a 3-point scale (0 absent, 1 intermittent, or 2 continuous). Results Significant improvements in the treatment group vs. baseline at Week 8 were an 84% decrease in mean average adenoidal-tissue size, compared with a 5% decrease in the control group (P less than 0.05) and an 80% decrease in snoring compared with a 5% decrease in the control group (P less than 0.05). Conclusions Once-daily MFNS 50 mcg is beneficial in the treatment of adenoidal hypertrophy and in reducing snoring in pediatric patients with AR.

scholarly journals Role of mometasone furoate nasal spray versus saline nasal spray in treatment of adenoid hypertrophy: a prospective, randomized study

2020 ◽  
Vol 6 (10) ◽  
pp. 1841
Author(s):  
Rabia Monga ◽  
Sanjeev Bhagat ◽  
Vishal Sharma ◽  
Dimple Sahni ◽  
Harjinder Singh ◽  
...  
Keyword(s):  
Nasal Obstruction ◽  
Nasal Spray ◽  
Clinical Symptoms ◽  
Randomized Study ◽  
Mometasone Furoate ◽  
Nasal Endoscopy ◽  
Prospective Randomized Study ◽  
Common Symptom ◽  
Adenoid Hypertrophy ◽  
Obstructive Sleep

<p class="abstract"><strong>Background: </strong>Adenoid hypertrophy is a common disorder in the paediatric population, presenting with multiple signs and symptoms ranging from nasal obstruction to obstructive sleep apnoea. Most common symptom is usually nasal airway obstruction. This prospective, randomized study aims to evaluate the efficacy of mometasone furoate spray in reducing size and clinical symptoms in patients with adenoid hypertrophy compared to saline spray.</p><p class="abstract"><strong>Methods:</strong> 60 patients in the age group of 3-11 years were enrolled in the study. Five symptoms were included that were hypo nasal speech, snoring, night cough, open mouth breathing and nasal obstruction which were scored as never=0, mild (sometimes)=1, moderate (less than 50% of times)=2, and severe (constant)=3. Diagnosis of adenoid hypertrophy was made on basis of nasal endoscopy.</p><p class="abstract"><strong>Results:</strong> Significant improvement was seen in individual as well as overall symptom score in group A as compared to group B after 8 weeks of treatment (p&lt;0.001). There was significant improvement in mean adenoid grade as per nasal endoscopy at 8 weeks post therapy (p&lt;0.001) which was not seen after 4 weeks of therapy.</p><p class="abstract"><strong>Conclusion:</strong> Intranasal steroid sprays have good role in decreasing the symptoms of adenoid hypertrophy and has reduced number of adenoidectomies required. The long-term effects as well as optimal duration of therapy is still controversial and needs to be studied further.</p>

Sign in / Sign up

Export Citation Format

Share Document